Literature DB >> 26082511

Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.

Jeffrey M Collins1, Kara Loren Raphael2, Charles Terry2, Emily J Cartwright3, Anjana Pillai4, Frank A Anania5, Monica M Farley3.   

Abstract

Treatment of hepatitis C virus with potent, interferon-free, direct-acting antiviral regimens with no activity against hepatitis B virus (HBV) may increase the risk for HBV reactivation in coinfected patients. We present 2 cases of HBV reactivation during treatment with an all-oral regimen of simeprevir and sofosbuvir and discuss strategies to prevent HBV flare.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HBV reactivation; HBV/HCV coinfection; acute hepatitis; simeprevir; sofosbuvir

Mesh：

Substances：

Year:  2015        PMID： 26082511     DOI： 10.1093/cid/civ474

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  41 in total

Review 1.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

2.  Editorial Commentary: Another Call to Cure Hepatitis B.

Authors:  Ashwin Balagopal; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2015-06-16       Impact factor: 9.079

Review 3.  Controversies in hepatitis C therapy: Reactivation of hepatitis B virus.

Authors:  Sarah R Lieber; Michael W Fried
Journal:  Clin Liver Dis (Hoboken)       Date:  2017-10-31

4.  HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use.

Authors:  Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

5.  Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.

Authors:  Anjana A Pillai; Frank A Anania; Brian L Pearlman
Journal:  Am J Gastroenterol       Date:  2016-12       Impact factor: 10.864

Review 6.  2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-08-10

Review 7.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

8.  When viruses collide: hepatitis B virus reactivation after hepatitis C treatment.

Authors:  Ashwin Balagopal; Chloe L Thio
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

9.  No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.

Authors:  Mark S Sulkowski; Wan-Long Chuang; Jia-Horng Kao; Jenny C Yang; Bing Gao; Diana M Brainard; Kwang-Hyub Han; Edward Gane
Journal:  Clin Infect Dis       Date:  2016-08-02       Impact factor: 9.079

10.  Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.

Authors:  M Serper; K A Forde; D E Kaplan
Journal:  J Viral Hepat       Date:  2017-09-21       Impact factor: 3.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.